Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 181

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 10
Chunk 181
---
.

 78Table of contents

Equity Compensation Plan Information

The following table summarizes information about our equity compensation plans as of December 31, 2024. All outstanding option awards relate to our common stock.

Plan Category Number of Securities tobe Issued UponExerciseof OutstandingOptions,Warrants andRights   Weighted- averageExercise Price ofOutstandingOptions,Warrants andRights   Number of Securities Remaining Available forFuture Issuance UnderEquity CompensationPlans(excluding securitiesreflected incolumn (a))    (a)  (b)  (c) Equity compensation plans approved by security holders:         2018 Equity Incentive Plan(1)  773,605  $1.84   755,618 Equity compensation plans not approved by security holders  -   -   - Total  773,605  $1.84   755,618 

(1)Our Board adopted, and our stockholders approved, our 2018 Plan. The 2018 Plan provides that the number of shares available for issuance under the 2018 Plan will be increased on the first day of each fiscal year beginning with the 2021 fiscal year, in an amount equal to the least of (i) 7,500,000 shares (subject to the reverse stock split), (ii) fifteen (15%) of the outstanding shares on the last day of the immediately preceding fiscal year or (iii) such other amount of shares determined by our board. 

 79Table of contents

Changes in Control

We are unaware of any contract or other arrangement or provisions of our Articles or Bylaws the operation of which may at a subsequent date result in a change of control of our company. 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Related Party Transactions

Described below are any transactions occurring since January 1, 2023 and any currently proposed transactions to which we were a party and in which:

 ·the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years; and ·a director, executive officer, holder of more than 5% of the outstanding capital stock of us, or any member of such person’s immediate family had or will have a direct or indirect material interest.

None.

Indemnification of Directors